AI
| Followers | 842 |
| Posts | 122793 |
| Boards Moderated | 10 |
| Alias Born | 09/05/2002 |
Tuesday, December 23, 2008 7:19:45 PM
Also-ran players in the US HIV market:
With Atripla and Truvada, GILD has established an 85% patient share in the first-line setting and a 67% patient share overall (#msg-32944110). Sustiva, Reyataz, and Kaletra (from BMY, BMY, and ABT, respectively) are large-selling drugs that fill out most of the Truvada-based cocktails.
So, who has the remaining crumbs?
Several companies do, as depicted by this
slide from MRK’s recent R&D webcast:
Note that these are patient shares, not Rx shares. (Rx shares are much smaller because nearly all non-Atripla patients take several HIV drugs simultaneously.)
With Atripla and Truvada, GILD has established an 85% patient share in the first-line setting and a 67% patient share overall (#msg-32944110). Sustiva, Reyataz, and Kaletra (from BMY, BMY, and ABT, respectively) are large-selling drugs that fill out most of the Truvada-based cocktails.
So, who has the remaining crumbs?
Several companies do, as depicted by this
slide from MRK’s recent R&D webcast:
Note that these are patient shares, not Rx shares. (Rx shares are much smaller because nearly all non-Atripla patients take several HIV drugs simultaneously.)
Trade Smarter with Thousands
Leverage decades of market experience shared openly.
